The company needed a hit in its spine trial, and it claims to have got one.
Protagonist Therapeutics and Pfizer will soon get an idea of their respective chances in beta-thalassaemia and Duchenne muscular dystrophy.
Europe and the US approvals of the ReStore device have arrived within a week; now the company must deliver commercially.
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
A poor quarter is followed by an acquisition, but is it big enough?
The upcoming American Academy of Neurology meeting could provide clues on how the market will shake out.
May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
A run of bad news leaves investors questioning Wave Life Sciences’ ability to deliver on its promises.
Filgotinib could be the safest Jak inhibitor yet, but Galapagos will need to make the most of this as it squares up to Abbvie.